Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 season - FluMist

Exclusion Criteria

• - Concurrent enrollment in another clinical study up to 180 days after receipt of investigational product (Day 181)
• - History of hypersensitivity to any component of the vaccine, including egg or egg protein or serious, life threatening, or severe reactions to previous influenza vaccinations
• - Any condition for which the inactivated influenza vaccine is indicated, including chronic disorders of the pulmonary or cardiovascular systems (example [eg], asthma), chronic metabolic diseases (eg, diabetes mellitus), renal dysfunction, or hemoglobinopathies that required regular medical follow-up or hospitalization during the preceding year
• - Acute febrile (greater than [>] 100.0 degrees Fahrenheit [F] oral or equivalent) and/or clinically significant respiratory illness (example, cough or sore throat) within 14 days to randomization
• - Any known immunosuppressive condition or immune deficiency diseases, including human immunodeficiency virus infection, or ongoing immunosuppressive therapy
• - History of Guillain-Barre syndrome
• - Receipt of any investigational agent within 30 days prior to randomization, or expected
• receipt through 30 days after the dose of investigational product (use of licensed agents
• for indications not listed in the Package Insert is permitted)
• - Receipt of any non-study vaccine within 30 days prior to randomization, or expected
• receipt through 30 days after receipt of investigational product
• - Expected receipt of antipyretic or analgesic medication on a daily or every other day basis from randomization through 14 days after receipt of investigational product
• - Administration of intranasal medications within 14 days prior to randomization, or expected receipt through 14 days after administration of investigational product
• - Receipt of influenza antiviral therapy or influenza antiviral agents within 48 hours prior to investigational product administration or expected receipt of influenza antiviral therapy or influenza antiviral agents through 14 days after receipt of investigational product